» Articles » PMID: 30963711

Fluorometholone Modulates Gene Expression of Ocular Surface Mucins

Overview
Journal Acta Ophthalmol
Specialty Ophthalmology
Date 2019 Apr 10
PMID 30963711
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Mucins are vital to keep the ocular surface hydrated. Genes encoding for mucins contain a glucocorticoid response element. The purpose of this study was to evaluate the effect of fluorometholone, a glucocorticoid receptor agonist used in the management of dry eye, on the gene expression of conjunctival and corneal epithelial cell mucins.

Methods: Stratified cultures of human conjunctival and corneal epithelial cells were exposed to 25, 50 and 100 nM of fluorometholone alone or in presence of mifepristone, a glucocorticoid receptor antagonist. The mRNA was isolated from the cells and reverse transcribed to cDNA. The cDNA was used for quantification of gene expression of mucin (MUC) 1, 4, 16 and 19 using real-time PCR.

Results: Fluorometholone caused a dose- and time-dependent increase in the gene expression of MUC1, MUC4, MUC16 and MUC19 in the conjunctival as well as corneal epithelial cells. Mifepristone, a glucocorticoid receptor antagonist, inhibited fluorometholone-mediated increase in the gene expression of conjunctival and corneal mucins. At the tested concentration, neither fluorometholone nor mifepristone caused any notable changes in the cellular phenotype or viability of conjunctival and corneal epithelial cells.

Conclusion: Fluorometholone increases the gene expression of MUC1, MUC4, MUC16 and MUC19 in the conjunctival and corneal epithelial cells through activation of glucocorticoid receptors. The increased expression of mucins can be an additional possible mechanism contributing to the beneficial effects of fluorometholone in dry eye in addition to its well-known anti-inflammatory effects.

Citing Articles

Global research hotspots and trends in anti-inflammatory studies in dry eye: a bibliometric analysis (2004-2024).

Wang S, Zheng W, Li T, Yu D, Zhang Q, Ju Y Front Med (Lausanne). 2024; 11:1451990.

PMID: 39669988 PMC: 11634594. DOI: 10.3389/fmed.2024.1451990.


Intricate insights into immune response in dry eye disease.

Kaur R, Gurnani B, Kaur K Indian J Ophthalmol. 2023; 71(4):1248-1255.

PMID: 37026255 PMC: 10276682. DOI: 10.4103/IJO.IJO_481_23.


Current Advances in Mechanisms and Treatment of Dry Eye Disease: Toward Anti-inflammatory and Immunomodulatory Therapy and Traditional Chinese Medicine.

Ling J, Chan B, Tsang M, Gao X, Leung P, Lam C Front Med (Lausanne). 2022; 8:815075.

PMID: 35111787 PMC: 8801439. DOI: 10.3389/fmed.2021.815075.


Membrane-associated mucins of the human ocular surface in health and disease.

Martinez-Carrasco R, Argueso P, Fini M Ocul Surf. 2021; 21:313-330.

PMID: 33775913 PMC: 8328898. DOI: 10.1016/j.jtos.2021.03.003.


Effect of High Glucose on Ocular Surface Epithelial Cell Barrier and Tight Junction Proteins.

Alfuraih S, Barbarino A, Ross C, Shamloo K, Jhanji V, Zhang M Invest Ophthalmol Vis Sci. 2020; 61(11):3.

PMID: 32876690 PMC: 7476661. DOI: 10.1167/iovs.61.11.3.